Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01169909 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
A Phase 1 study of Pterygium, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01169909: Completed Phase 1 study of Pterygium, sponsored by University of New Mexi.
NCT01169909 is a Phase 1 study of Pterygium that has completed, run by University of New Mexi. The registered enrollment target is 10 participants, below the 263-participant average among 3 other Pterygium trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01169909, a Phase 1 study of Pterygium, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Primary Outcome
The following safety criteria will be monitored: subjective complaints, objective signs of inflammation, intraocular pressure, tear film and ocular surface integrity.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (1)
New Mexico
- University of New Mexico Health Science Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
What the finished NCT01169909 record still lists
NCT01169909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 263-participant average among 3 other Pterygium trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pterygium appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT01169909 reports a single indexed study location in New Mexico.
Frequently Asked Questions
What is clinical trial NCT01169909 about?
NCT01169909 is a clinical study titled "Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia". Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
What is the current status of trial NCT01169909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-08. Estimated completion is 2014-07.
What conditions does trial NCT01169909 study?
This clinical trial studies the following conditions: Pterygium.
What interventions are being tested in trial NCT01169909?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01169909?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01169909 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pterygium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia